Inventor
FRASER GRAEME
BE17 patents
⚠️ This page may combine multiple inventors who share the name “FRASER GRAEME”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
OGEDA SA
9 patentsUS10836768B2Nov 17, 2020
N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists
OGEDA SA1 citations72
US10183948B2Jan 22, 2019
N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists
OGEDA SA1 citations72
US9987274B2Jun 5, 2018
N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists
OGEDA SA4 citations72
US9969745B2May 15, 2018
N-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders
OGEDA SA2 citations72
US11478472B2Oct 25, 2022
NK-3 receptor antagonists for therapeutic treatment of leptin-related disease
OGEDA SA1 citations71
US10624890B2Apr 21, 2020
NK-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat
OGEDA SA2 citations71
US11731974B2Aug 22, 2023
N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists
OGEDA SA0 citations62
US12458641B2Nov 4, 2025
NK-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat
OGEDA SA0 citations61
US10214533B2Feb 26, 2019
N-acyl-(3-substituted)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders
OGEDA SA0 citations51
EUROSCREEN SA
5 patentsUS9422299B2Aug 23, 2016
Substituted [1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists
EUROSCREEN SA17 citations91
US9969738B2May 15, 2018
N-acyl-(3-substituted)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders
EUROSCREEN SA2 citations72
US10030025B2Jul 24, 2018
Substituted [1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists
EUROSCREEN SA1 citations51
US9840508B2Dec 12, 2017
N-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a] pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders
EUROSCREEN SA0 citations51
US9770435B2Sep 26, 2017
Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
EUROSCREEN SA0 citations38